Personalized medicine in functional gastrointestinal disorders:Understanding pathogenesis to increase diagnostic and treatment efficacy
|
摘要
There is overwhelming evidence that functional gastrointestinal disorders(FGIDs) are associated with specific mechanisms that constitute important targets for personalized treatment. There are specific mechanisms in patients presenting with functional upper gastrointestinal symptoms(UGI Sx). Among patients with UGI Sx, approximately equal proportions(25%) of patients have delayed gastric emptying(GE), reduced gastric accommodation(GA), both impaired GE and GA,or neither, presumably due to increased gastric or duodenal sensitivity.Treatments targeted to the underlying pathophysiology utilize prokinetics,gastric relaxants, or central neuromodulators. Similarly, specific mechanisms in patients presenting with functional lower gastrointestinal symptoms, especially with diarrhea or constipation, are recognized, including at least 30% of patients with functional constipation pelvic floor dyssynergia and 5% has colonic inertia(with neural or interstitial cells of Cajal loss in myenteric plexus); 25% of patients with diarrhea-predominant irritable bowel syndrome(IBSD) has evidence of bile acid diarrhea; and, depending on ethnicity, a varying proportion of patients has disaccharidase deficiency, and less often sucrose-isomaltase deficiency. Among patients with predominant pain or bloating, the role of fermentable oligosaccharides, disaccharides, monosaccharides and polyols should be considered. Personalization is applied through pharmacogenomics related to drug pharmacokinetics, specifically the role of CYP2 D6, 2 C19 and 3 A4 in the use of drugs for treatment of patients with FGIDs. Single mutations or multiple genetic variants are relatively rare, with limited impact to date on the understanding or treatment of FGIDs. The role of mucosal gene expression in FGIDs, particularly in IBS-D, is the subject of ongoing research. In summary, the time for personalization of FGIDs, based on deep phenotyping, is here;pharmacogenomics is relevant in the use of central neuromodulators. There is still unclear impact of the role of genetics in the management of FGIDs.
There is overwhelming evidence that functional gastrointestinal disorders(FGIDs) are associated with specific mechanisms that constitute important targets for personalized treatment. There are specific mechanisms in patients presenting with functional upper gastrointestinal symptoms(UGI Sx). Among patients with UGI Sx, approximately equal proportions(25%) of patients have delayed gastric emptying(GE), reduced gastric accommodation(GA), both impaired GE and GA,or neither, presumably due to increased gastric or duodenal sensitivity.Treatments targeted to the underlying pathophysiology utilize prokinetics,gastric relaxants, or central neuromodulators. Similarly, specific mechanisms in patients presenting with functional lower gastrointestinal symptoms, especially with diarrhea or constipation, are recognized, including at least 30% of patients with functional constipation pelvic floor dyssynergia and 5% has colonic inertia(with neural or interstitial cells of Cajal loss in myenteric plexus); 25% of patients with diarrhea-predominant irritable bowel syndrome(IBSD) has evidence of bile acid diarrhea; and, depending on ethnicity, a varying proportion of patients has disaccharidase deficiency, and less often sucrose-isomaltase deficiency. Among patients with predominant pain or bloating, the role of fermentable oligosaccharides, disaccharides, monosaccharides and polyols should be considered. Personalization is applied through pharmacogenomics related to drug pharmacokinetics, specifically the role of CYP2 D6, 2 C19 and 3 A4 in the use of drugs for treatment of patients with FGIDs. Single mutations or multiple genetic variants are relatively rare, with limited impact to date on the understanding or treatment of FGIDs. The role of mucosal gene expression in FGIDs, particularly in IBS-D, is the subject of ongoing research. In summary, the time for personalization of FGIDs, based on deep phenotyping, is here;pharmacogenomics is relevant in the use of central neuromodulators. There is still unclear impact of the role of genetics in the management of FGIDs.
There is overwhelming evidence that functional gastrointestinal disorders(FGIDs) are associated with specific mechanisms that constitute important targets for personalized treatment. There are specific mechanisms in patients presenting with functional upper gastrointestinal symptoms(UGI Sx). Among patients with UGI Sx, approximately equal proportions(25%) of patients have delayed gastric emptying(GE), reduced gastric accommodation(GA), both impaired GE and GA,or neither, presumably due to increased gastric or duodenal sensitivity.Treatments targeted to the underlying pathophysiology utilize prokinetics,gastric relaxants, or central neuromodulators. Similarly, specific mechanisms in patients presenting with functional lower gastrointestinal symptoms, especially with diarrhea or constipation, are recognized, including at least 30% of patients with functional constipation pelvic floor dyssynergia and 5% has colonic inertia(with neural or interstitial cells of Cajal loss in myenteric plexus); 25% of patients with diarrhea-predominant irritable bowel syndrome(IBSD) has evidence of bile acid diarrhea; and, depending on ethnicity, a varying proportion of patients has disaccharidase deficiency, and less often sucrose-isomaltase deficiency. Among patients with predominant pain or bloating, the role of fermentable oligosaccharides, disaccharides, monosaccharides and polyols should be considered. Personalization is applied through pharmacogenomics related to drug pharmacokinetics, specifically the role of CYP2 D6, 2 C19 and 3 A4 in the use of drugs for treatment of patients with FGIDs. Single mutations or multiple genetic variants are relatively rare, with limited impact to date on the understanding or treatment of FGIDs. The role of mucosal gene expression in FGIDs, particularly in IBS-D, is the subject of ongoing research. In summary, the time for personalization of FGIDs, based on deep phenotyping, is here;pharmacogenomics is relevant in the use of central neuromodulators. There is still unclear impact of the role of genetics in the management of FGIDs.
引文
1 Drossman DA.The functional gastrointestinal disorders and the Rome III process.Gastroenterology2006;130:1377-1390[PMID:16678553 DOI:10.1053/j.gastro.2006.03.008]
2 Saito YA,Schoenfeld P,Locke GR.The epidemiology of irritable bowel syndrome in North America:a systematic review.Am J Gastroenterol 2002;97:1910-1915[PMID:12190153 DOI:10.1111/j.1572-0241.2002.05913.x]
3 Oshima T,Miwa H.Epidemiology of Functional Gastrointestinal Disorders in Japan and in the World.JNeurogastroenterol Motil 2015;21:320-329[PMID:26095436 DOI:10.5056/jnm14165]
4 Tjeerdsma HC,Smout AJ,Akkermans LM.Voluntary suppression of defecation delays gastric emptying.Dig Dis Sci 1993;38:832-836[PMID:8482181]
5 Shivaji UN,Ford AC.Prevalence of functional gastrointestinal disorders among consecutive new patient referrals to a gastroenterology clinic.Frontline Gastroenterol 2014;5:266-271[PMID:28839783 DOI:10.1136/flgastro-2013-100426]
6 Ford AC,Marwaha A,Lim A,Moayyedi P.What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia?Systematic review and meta-analysis.Clin Gastroenterol Hepatol2010;8:830-837,837.e1-837.e2[PMID:20541625 DOI:10.1016/j.cgh.2010.05.031]
7 Hamm LR,Sorrells SC,Harding JP,Northcutt AR,Heath AT,Kapke GF,Hunt CM,Mangel AW.Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria.Am J Gastroenterol 1999;94:1279-1282[PMID:10235207 DOI:10.1111/j.1572-0241.1999.01077.x]
8 Manning AP,Thompson WG,Heaton KW,Morris AF.Towards positive diagnosis of the irritable bowel.Br Med J 1978;2:653-654[PMID:698649]
9 Moayyedi P,Mearin F,Azpiroz F,Andresen V,Barbara G,Corsetti M,Emmanuel A,Hungin APS,Layer P,Stanghellini V,Whorwell P,Zerbib F,Tack J.Irritable bowel syndrome diagnosis and management:Asimplified algorithm for clinical practice.United European Gastroenterol J 2017;5:773-788[PMID:29026591 DOI:10.1177/2050640617731968]
10 Camilleri M.Peripheral mechanisms in irritable bowel syndrome.N Engl J Med 2012;367:1626-1635[PMID:23094724 DOI:10.1056/NEJMra1207068]
11 Chang L,Heitkemper MM,Wiley JW,Camilleri M.2015 James W.Freston Single Topic Conference:ARenaissance in the Understanding and Management of Irritable Bowel Syndrome.Gastroenterology 2016;151:e1-e8[PMID:27215658 DOI:10.1053/j.gastro.2016.05.010]
12 Stanghellini V,Chan FK,Hasler WL,Malagelada JR,Suzuki H,Tack J,Talley NJ.Gastroduodenal Disorders.Gastroenterology 2016;150:1380-1392[PMID:27147122 DOI:10.1053/j.gastro.2016.02.011]
13 Park SY,Acosta A,Camilleri M,Burton D,Harmsen WS,Fox J,Szarka LA.Gastric Motor Dysfunction in Patients With Functional Gastroduodenal Symptoms.Am J Gastroenterol 2017;112:1689-1699[PMID:28895582 DOI:10.1038/ajg.2017.264]
14 Vijayvargiya P,Jameie-Oskooei S,Camilleri M,Chedid V,Erwin PJ,Murad MH.Association between delayed gastric emptying and upper gastrointestinal symptoms:a systematic review and meta-analysis.Gut2018[PMID:29860241 DOI:10.1136/gutjnl-2018-316405]
15 Pathikonda M,Sachdeva P,Malhotra N,Fisher RS,Maurer AH,Parkman HP.Gastric emptying scintigraphy:is four hours necessary?J Clin Gastroenterol 2012;46:209-215[PMID:21959322 DOI:10.1097/MCG.0b013e31822f3ad2]
16 Carbone F,Vanuytsel T,Tack J.The effect of mirtazapine on gastric accommodation,gastric sensitivity to distention,and nutrient tolerance in healthy subjects.Neurogastroenterol Motil 2017;29[PMID:28695632 DOI:10.1111/nmo.13146]
17 Lembo A,Camilleri M,McCallum R,Sastre R,Breton C,Spence S,White J,Currie M,Gottesdiener K,Stoner E;RM-131-004 Trial Group.Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis.Gastroenterology 2016;151:87-96.e6[PMID:27055601 DOI:10.1053/j.gastro.2016.03.038]
18 Camilleri M,McCallum RW,Tack J,Spence SC,Gottesdiener K,Fiedorek FT.Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis:A Randomized,Placebo-Controlled Study.Gastroenterology 2017;153:1240-1250.e2[PMID:28760384 DOI:10.1053/j.gastro.2017.07.035]
19 Kusunoki H,Haruma K,Manabe N,Imamura H,Kamada T,Shiotani A,Hata J,Sugioka H,Saito Y,Kato H,Tack J.Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying:randomized controlled study evaluation by real-time ultrasonography.Neurogastroenterol Motil 2012;24:540-545,e250-e251[PMID:22385472 DOI:10.1111/j.1365-2982.2012.01897.x]
20 Mearin F,Lacy BE,Chang L,Chey WD,Lembo AJ,Simren M,Spiller R.Bowel Disorders.Gastroenterology 2016[PMID:27144627 DOI:10.1053/j.gastro.2016.02.031]
21 American Gastroenterological Association;Bharucha AE,Dorn SD,Lembo A,Pressman A.American Gastroenterological Association medical position statement on constipation.Gastroenterology 2013;144:211-217[PMID:23261064 DOI:10.1053/j.gastro.2012.10.029]
22 Chedid V,Vijayvargiya P,Halawi H,Park SY,Camilleri M.Audit of the diagnosis of rectal evacuation disorders in chronic constipation.Neurogastroenterol Motil 2019;31:e13510[PMID:30426597 DOI:10.1111/nmo.13510]
23 Harewood GC,Coulie B,Camilleri M,Rath-Harvey D,Pemberton JH.Descending perineum syndrome:audit of clinical and laboratory features and outcome of pelvic floor retraining.Am J Gastroenterol 1999;94:126-130[PMID:9934742 DOI:10.1111/j.1572-0241.1999.00782.x]
24 Vijayvargiya P,Camilleri M,Cima RR.COL1A1 Mutations Presenting as Descending Perineum Syndrome in a Young Patient With Hypermobility Syndrome.Mayo Clin Proc 2018;93:386-391[PMID:29502568 DOI:10.1016/j.mayocp.2018.01.007]
25 Flusberg M,Sahni VA,Erturk SM,Mortele KJ.Dynamic MR defecography:assessment of the usefulness of the defecation phase.AJR Am J Roentgenol 2011;196:W394-W399[PMID:21427302 DOI:10.2214/AJR.10.4445]
26 Kim ER,Rhee PL.How to interpret a functional or motility test-colon transit study.JNeurogastroenterol Motil 2012;18:94-99[PMID:22323993 DOI:10.5056/jnm.2012.18.1.94]
27 Patcharatrakul T,Valestin J,Schmeltz A,Schulze K,Rao SSC.Factors Associated With Response to Biofeedback Therapy for Dyssynergic Defecation.Clin Gastroenterol Hepatol 2018;16:715-721[PMID:29111136 DOI:10.1016/j.cgh.2017.10.027]
28 Rao SSC,Valestin JA,Xiang X,Hamdy S,Bradley CS,Zimmerman MB.Home-based versus officebased biofeedback therapy for constipation with dyssynergic defecation:a randomised controlled trial.Lancet Gastroenterol Hepatol 2018;3:768-777[PMID:30236904 DOI:10.1016/S2468-1253(18)30266-8]
29 Rao SS,Valestin J,Brown CK,Zimmerman B,Schulze K.Long-term efficacy of biofeedback therapy for dyssynergic defecation:randomized controlled trial.Am J Gastroenterol 2010;105:890-896[PMID:20179692 DOI:10.1038/ajg.2010.53]
30 Lee YY,Erdogan A,Rao SS.How to perform and assess colonic manometry and barostat study in chronic constipation.J Neurogastroenterol Motil 2014;20:547-552[PMID:25230902 DOI:10.5056/jnm14056]
31 Parthasarathy G,Ravi K,Camilleri M,Andrews C,Szarka LA,Low PA,Zinsmeister AR,Bharucha AE.Effect of neostigmine on gastroduodenal motility in patients with suspected gastrointestinal motility disorders.Neurogastroenterol Motil 2015;27:1736-1746[PMID:26387781 DOI:10.1111/nmo.12669]
32 Bharucha AE,Low PA,Camilleri M,Burton D,Gehrking TL,Zinsmeister AR.Pilot study of pyridostigmine in constipated patients with autonomic neuropathy.Clin Auton Res 2008;18:194-202[PMID:18622640 DOI:10.1007/s10286-008-0476-x]
33 Wedlake L,A'Hern R,Russell D,Thomas K,Walters JR,Andreyev HJ.Systematic review:the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome.Aliment Pharmacol Ther 2009;30:707-717[PMID:19570102 DOI:10.1111/j.1365-2036.2009.04081.x]
34 Johnston IM,Nolan JD,Pattni SS,Appleby RN,Zhang JH,Kennie SL,Madhan GK,Jameie-Oskooei S,Pathmasrirengam S,Lin J,Hong A,Dixon PH,Williamson C,Walters JR.Characterizing Factors Associated With Differences in FGF19 Blood Levels and Synthesis in Patients With Primary Bile Acid Diarrhea.Am J Gastroenterol 2016;111:423-432[PMID:26856750 DOI:10.1038/ajg.2015.424]
35 Wong BS,Camilleri M,Carlson PJ,Guicciardi ME,Burton D,McKinzie S,Rao AS,Zinsmeister AR,Gores GJ.A Klothoβvariant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea.Gastroenterology 2011;140:1934-1942[PMID:21396369 DOI:10.1053/j.gastro.2011.02.063]
36 Camilleri M.Bile Acid diarrhea:prevalence,pathogenesis,and therapy.Gut Liver 2015;9:332-339[PMID:25918262 DOI:10.5009/gnl14397]
37 Peleman C,Camilleri M,Busciglio I,Burton D,Donato L,Zinsmeister AR.Colonic Transit and Bile Acid Synthesis or Excretion in Patients With Irritable Bowel Syndrome-Diarrhea Without Bile Acid Malabsorption.Clin Gastroenterol Hepatol 2017;15:720-727.e1[PMID:27856362 DOI:10.1016/j.cgh.2016.11.012]
38 Sauter GH,Münzing W,von Ritter C,Paumgartner G.Bile acid malabsorption as a cause of chronic diarrhea:diagnostic value of 7alpha-hydroxy-4-cholesten-3-one in serum.Dig Dis Sci 1999;44:14-19[PMID:9952217]
39 Lomer MC,Parkes GC,Sanderson JD.Review article:lactose intolerance in clinical practice--myths and realities.Aliment Pharmacol Ther 2008;27:93-103[PMID:17956597 DOI:10.1111/j.1365-2036.2007.03557.x]
40 Deng Y,Misselwitz B,Dai N,Fox M.Lactose Intolerance in Adults:Biological Mechanism and Dietary Management.Nutrients 2015;7:8020-8035[PMID:26393648 DOI:10.3390/nu7095380]
41 Tolliver BA,Herrera JL,DiPalma JA.Evaluation of patients who meet clinical criteria for irritable bowel syndrome.Am J Gastroenterol 1994;89:176-178[PMID:8304298]
42 Suarez FL,Savaiano DA,Levitt MD.A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance.N Engl J Med 1995;333:1-4[PMID:7776987 DOI:10.1056/NEJM199507063330101]
43 Wilder-Smith CH,Olesen SS,Materna A,Drewes AM.Fermentable Sugar Ingestion,Gas Production,and Gastrointestinal and Central Nervous System Symptoms in Patients With Functional Disorders.Gastroenterology 2018;155:1034-1044.e6[PMID:30009815 DOI:10.1053/j.gastro.2018.07.013]
44 Townley RR,Khaw KT,Shwachman H.Quantitative assay of disaccharidase activities of small intestinal mucosal biopsy specimens in infancy and childhood.Pediatrics 1965;36:911-921[PMID:5846834]
45 Saulnier DM,Ringel Y,Heyman MB,Foster JA,Bercik P,Shulman RJ,Versalovic J,Verdu EF,Dinan TG,Hecht G,Guarner F.The intestinal microbiome,probiotics and prebiotics in neurogastroenterology.Gut Microbes 2013;4:17-27[PMID:23202796 DOI:10.4161/gmic.22973]
46 Quigley EMM.Prebiotics and Probiotics in Digestive Health.Clin Gastroenterol Hepatol 2019;17:333-344[PMID:30267869 DOI:10.1016/j.cgh.2018.09.028]
47 Schnabel L,Buscail C,Sabate JM,Bouchoucha M,Kesse-Guyot E,Allès B,Touvier M,Monteiro CA,Hercberg S,Benamouzig R,Julia C.Association Between Ultra-Processed Food Consumption and Functional Gastrointestinal Disorders:Results From the French NutriNet-SantéCohort.Am JGastroenterol 2018;113:1217-1228[PMID:29904158 DOI:10.1038/s41395-018-0137-1]
48 Mayer EA,Savidge T,Shulman RJ.Brain-gut microbiome interactions and functional bowel disorders.Gastroenterology 2014;146:1500-1512[PMID:24583088 DOI:10.1053/j.gastro.2014.02.037]
49 Levy RL,Olden KW,Naliboff BD,Bradley LA,Francisconi C,Drossman DA,Creed F.Psychosocial aspects of the functional gastrointestinal disorders.Gastroenterology 2006;130:1447-1458[PMID:16678558 DOI:10.1053/j.gastro.2005.11.057]
50 De Palma G,Lynch MD,Lu J,Dang VT,Deng Y,Jury J,Umeh G,Miranda PM,Pigrau Pastor M,Sidani S,Pinto-Sanchez MI,Philip V,McLean PG,Hagelsieb MG,Surette MG,Bergonzelli GE,Verdu EF,Britz-McKibbin P,Neufeld JD,Collins SM,Bercik P.Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice.Sci Transl Med 2017;9[PMID:28251905 DOI:10.1126/scitranslmed.aaf6397]
51 Palsson OS,Whitehead WE.Psychological treatments in functional gastrointestinal disorders:a primer for the gastroenterologist.Clin Gastroenterol Hepatol 2013;11:208-16;quiz e22-3[PMID:23103907 DOI:10.1016/j.cgh.2012.10.031]
52 Bednarska O,Walter SA,Casado-Bedmar M,Str?m M,Salvo-Romero E,Vicario M,Mayer EA,Keita?V.Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome.Gastroenterology 2017;153:948-960.e3[PMID:28711627 DOI:10.1053/j.gastro.2017.06.051]
53 Camilleri M,Lasch K,Zhou W.Irritable bowel syndrome:methods,mechanisms,and pathophysiology.The confluence of increased permeability,inflammation,and pain in irritable bowel syndrome.Am JPhysiol Gastrointest Liver Physiol 2012;303:G775-G785[PMID:22837345 DOI:10.1152/ajpgi.00155.2012]
54 Turcotte JF,Kao D,Mah SJ,Claggett B,Saltzman JR,Fedorak RN,Liu JJ.Breaks in the wall:increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy(with videos).Gastrointest Endosc 2013;77:624-630[PMID:23357497 DOI:10.1016/j.gie.2012.11.006]
55 Fritscher-Ravens A,Schuppan D,Ellrichmann M,Schoch S,R?cken C,Brasch J,Bethge J,B?ttner M,Klose J,Milla PJ.Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome.Gastroenterology 2014;147:1012-20.e4[PMID:25083606 DOI:10.1053/j.gastro.2014.07.046]
56 Witt ST,Bednarska O,Keita?V,Icenhour A,Jones MP,Elsenbruch S,S?derholm JD,Engstr?m M,Mayer EA,Walter S.Interactions between gut permeability and brain structure and function in health and irritable bowel syndrome.Neuroimage Clin 2018[PMID:30472166 DOI:10.1016/j.nicl.2018.11.012]
57 Ma ZF,Yusof N,Hamid N,Lawenko RM,Mohammad WMZW,Liong MT,Sugahara H,Odamaki T,Xiao J,Lee YY.Bifidobacterium infantis M-63 improves mental health in victims with irritable bowel syndrome developed after a major flood disaster.Benef Microbes 2018;1-10[PMID:30525951 DOI:10.3920/BM2018.0008]
58 Vaughn BP,Rank KM,Khoruts A.Fecal Microbiota Transplantation:Current Status in Treatment of GIand Liver Disease.Clin Gastroenterol Hepatol 2019;17:353-361[PMID:30055267 DOI:10.1016/j.cgh.2018.07.026]
59 Drossman DA,Tack J,Ford AC,Szigethy E,T?rnblom H,Van Oudenhove L.Neuromodulators for Functional Gastrointestinal Disorders(Disorders of Gut-Brain Interaction):A Rome Foundation Working Team Report.Gastroenterology 2018;154:1140-1171.e1[PMID:29274869 DOI:10.1053/j.gastro.2017.11.279]
60 D'Souza DL,Levasseur LM,Nezamis J,Robbins DK,Simms L,Koch KM.Effect of alosetron on the pharmacokinetics of alprazolam.J Clin Pharmacol 2001;41:452-454[PMID:11304902]
61 Camilleri M.The role of pharmacogenetics in nonmalignant gastrointestinal diseases.Nat Rev Gastroenterol Hepatol 2012;9:173-184[PMID:22310916 DOI:10.1038/nrgastro.2012.2]
62 Li Y,Nie Y,Xie J,Tang W,Liang P,Sha W,Yang H,Zhou Y.The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients.Dig Dis Sci 2007;52:2942-2949[PMID:17394071 DOI:10.1007/s10620-006-9679-y]
63 Camilleri M,Carlson P,Acosta A,Busciglio I,Nair AA,Gibbons SJ,Farrugia G,Klee EW.RNAsequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea:a pilot case-control study.Am J Physiol Gastrointest Liver Physiol 2014;306:G1089-G1098[PMID:24763552 DOI:10.1152/ajpgi.00068.2014]
64 Camilleri M,Carlson P,Valentin N,Acosta A,O'Neill J,Eckert D,Dyer R,Na J,Klee EW,Murray JA.Pilot study of small bowel mucosal gene expression in patients with irritable bowel syndrome with diarrhea.Am J Physiol Gastrointest Liver Physiol 2016;311:G365-G376[PMID:27445342 DOI:10.1152/ajpgi.00037.2016]
65 Gikas A,Triantafillidis JK.The role of primary care physicians in early diagnosis and treatment of chronic gastrointestinal diseases.Int J Gen Med 2014;7:159-173[PMID:24648750 DOI:10.2147/IJGM.S58888]
66 Tack J,Pokrotnieks J,Urbonas G,Banciu C,Yakusevich V,Bunganic I,T?rnblom H,Kleban Y,Eavis P,Tsuchikawa M,Miyagawa T.Long-term safety and efficacy of acotiamide in functional dyspepsia(postprandial distress syndrome)-results from the European phase 3 open-label safety trial.Neurogastroenterol Motil 2018;30:e13284[PMID:29315999 DOI:10.1111/nmo.13284]
67 Camilleri M,Acosta A,Busciglio I,Boldingh A,Dyer RB,Zinsmeister AR,Lueke A,Gray A,Donato LJ.Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome.Aliment Pharmacol Ther 2015;41:438-448[PMID:25594801 DOI:10.1111/apt.13065]
68 Wilcox C,Turner J,Green J.Systematic review:the management of chronic diarrhoea due to bile acid malabsorption.Aliment Pharmacol Ther 2014;39:923-939[PMID:24602022 DOI:10.1111/apt.12684]
69 Camilleri M,Kerstens R,Rykx A,Vandeplassche L.A placebo-controlled trial of prucalopride for severe chronic constipation.N Engl J Med 2008;358:2344-2354[PMID:18509121 DOI:10.1056/NEJ-Moa0800670]
70 Ford AC,Brandt LJ,Young C,Chey WD,Foxx-Orenstein AE,Moayyedi P.Efficacy of 5-HT3antagonists and 5-HT4 agonists in irritable bowel syndrome:systematic review and meta-analysis.Am JGastroenterol 2009;104:1831-1843;quiz 1844[PMID:19471254 DOI:10.1038/ajg.2009.223]
2 Saito YA,Schoenfeld P,Locke GR.The epidemiology of irritable bowel syndrome in North America:a systematic review.Am J Gastroenterol 2002;97:1910-1915[PMID:12190153 DOI:10.1111/j.1572-0241.2002.05913.x]
3 Oshima T,Miwa H.Epidemiology of Functional Gastrointestinal Disorders in Japan and in the World.JNeurogastroenterol Motil 2015;21:320-329[PMID:26095436 DOI:10.5056/jnm14165]
4 Tjeerdsma HC,Smout AJ,Akkermans LM.Voluntary suppression of defecation delays gastric emptying.Dig Dis Sci 1993;38:832-836[PMID:8482181]
5 Shivaji UN,Ford AC.Prevalence of functional gastrointestinal disorders among consecutive new patient referrals to a gastroenterology clinic.Frontline Gastroenterol 2014;5:266-271[PMID:28839783 DOI:10.1136/flgastro-2013-100426]
6 Ford AC,Marwaha A,Lim A,Moayyedi P.What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia?Systematic review and meta-analysis.Clin Gastroenterol Hepatol2010;8:830-837,837.e1-837.e2[PMID:20541625 DOI:10.1016/j.cgh.2010.05.031]
7 Hamm LR,Sorrells SC,Harding JP,Northcutt AR,Heath AT,Kapke GF,Hunt CM,Mangel AW.Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria.Am J Gastroenterol 1999;94:1279-1282[PMID:10235207 DOI:10.1111/j.1572-0241.1999.01077.x]
8 Manning AP,Thompson WG,Heaton KW,Morris AF.Towards positive diagnosis of the irritable bowel.Br Med J 1978;2:653-654[PMID:698649]
9 Moayyedi P,Mearin F,Azpiroz F,Andresen V,Barbara G,Corsetti M,Emmanuel A,Hungin APS,Layer P,Stanghellini V,Whorwell P,Zerbib F,Tack J.Irritable bowel syndrome diagnosis and management:Asimplified algorithm for clinical practice.United European Gastroenterol J 2017;5:773-788[PMID:29026591 DOI:10.1177/2050640617731968]
10 Camilleri M.Peripheral mechanisms in irritable bowel syndrome.N Engl J Med 2012;367:1626-1635[PMID:23094724 DOI:10.1056/NEJMra1207068]
11 Chang L,Heitkemper MM,Wiley JW,Camilleri M.2015 James W.Freston Single Topic Conference:ARenaissance in the Understanding and Management of Irritable Bowel Syndrome.Gastroenterology 2016;151:e1-e8[PMID:27215658 DOI:10.1053/j.gastro.2016.05.010]
12 Stanghellini V,Chan FK,Hasler WL,Malagelada JR,Suzuki H,Tack J,Talley NJ.Gastroduodenal Disorders.Gastroenterology 2016;150:1380-1392[PMID:27147122 DOI:10.1053/j.gastro.2016.02.011]
13 Park SY,Acosta A,Camilleri M,Burton D,Harmsen WS,Fox J,Szarka LA.Gastric Motor Dysfunction in Patients With Functional Gastroduodenal Symptoms.Am J Gastroenterol 2017;112:1689-1699[PMID:28895582 DOI:10.1038/ajg.2017.264]
14 Vijayvargiya P,Jameie-Oskooei S,Camilleri M,Chedid V,Erwin PJ,Murad MH.Association between delayed gastric emptying and upper gastrointestinal symptoms:a systematic review and meta-analysis.Gut2018[PMID:29860241 DOI:10.1136/gutjnl-2018-316405]
15 Pathikonda M,Sachdeva P,Malhotra N,Fisher RS,Maurer AH,Parkman HP.Gastric emptying scintigraphy:is four hours necessary?J Clin Gastroenterol 2012;46:209-215[PMID:21959322 DOI:10.1097/MCG.0b013e31822f3ad2]
16 Carbone F,Vanuytsel T,Tack J.The effect of mirtazapine on gastric accommodation,gastric sensitivity to distention,and nutrient tolerance in healthy subjects.Neurogastroenterol Motil 2017;29[PMID:28695632 DOI:10.1111/nmo.13146]
17 Lembo A,Camilleri M,McCallum R,Sastre R,Breton C,Spence S,White J,Currie M,Gottesdiener K,Stoner E;RM-131-004 Trial Group.Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis.Gastroenterology 2016;151:87-96.e6[PMID:27055601 DOI:10.1053/j.gastro.2016.03.038]
18 Camilleri M,McCallum RW,Tack J,Spence SC,Gottesdiener K,Fiedorek FT.Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis:A Randomized,Placebo-Controlled Study.Gastroenterology 2017;153:1240-1250.e2[PMID:28760384 DOI:10.1053/j.gastro.2017.07.035]
19 Kusunoki H,Haruma K,Manabe N,Imamura H,Kamada T,Shiotani A,Hata J,Sugioka H,Saito Y,Kato H,Tack J.Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying:randomized controlled study evaluation by real-time ultrasonography.Neurogastroenterol Motil 2012;24:540-545,e250-e251[PMID:22385472 DOI:10.1111/j.1365-2982.2012.01897.x]
20 Mearin F,Lacy BE,Chang L,Chey WD,Lembo AJ,Simren M,Spiller R.Bowel Disorders.Gastroenterology 2016[PMID:27144627 DOI:10.1053/j.gastro.2016.02.031]
21 American Gastroenterological Association;Bharucha AE,Dorn SD,Lembo A,Pressman A.American Gastroenterological Association medical position statement on constipation.Gastroenterology 2013;144:211-217[PMID:23261064 DOI:10.1053/j.gastro.2012.10.029]
22 Chedid V,Vijayvargiya P,Halawi H,Park SY,Camilleri M.Audit of the diagnosis of rectal evacuation disorders in chronic constipation.Neurogastroenterol Motil 2019;31:e13510[PMID:30426597 DOI:10.1111/nmo.13510]
23 Harewood GC,Coulie B,Camilleri M,Rath-Harvey D,Pemberton JH.Descending perineum syndrome:audit of clinical and laboratory features and outcome of pelvic floor retraining.Am J Gastroenterol 1999;94:126-130[PMID:9934742 DOI:10.1111/j.1572-0241.1999.00782.x]
24 Vijayvargiya P,Camilleri M,Cima RR.COL1A1 Mutations Presenting as Descending Perineum Syndrome in a Young Patient With Hypermobility Syndrome.Mayo Clin Proc 2018;93:386-391[PMID:29502568 DOI:10.1016/j.mayocp.2018.01.007]
25 Flusberg M,Sahni VA,Erturk SM,Mortele KJ.Dynamic MR defecography:assessment of the usefulness of the defecation phase.AJR Am J Roentgenol 2011;196:W394-W399[PMID:21427302 DOI:10.2214/AJR.10.4445]
26 Kim ER,Rhee PL.How to interpret a functional or motility test-colon transit study.JNeurogastroenterol Motil 2012;18:94-99[PMID:22323993 DOI:10.5056/jnm.2012.18.1.94]
27 Patcharatrakul T,Valestin J,Schmeltz A,Schulze K,Rao SSC.Factors Associated With Response to Biofeedback Therapy for Dyssynergic Defecation.Clin Gastroenterol Hepatol 2018;16:715-721[PMID:29111136 DOI:10.1016/j.cgh.2017.10.027]
28 Rao SSC,Valestin JA,Xiang X,Hamdy S,Bradley CS,Zimmerman MB.Home-based versus officebased biofeedback therapy for constipation with dyssynergic defecation:a randomised controlled trial.Lancet Gastroenterol Hepatol 2018;3:768-777[PMID:30236904 DOI:10.1016/S2468-1253(18)30266-8]
29 Rao SS,Valestin J,Brown CK,Zimmerman B,Schulze K.Long-term efficacy of biofeedback therapy for dyssynergic defecation:randomized controlled trial.Am J Gastroenterol 2010;105:890-896[PMID:20179692 DOI:10.1038/ajg.2010.53]
30 Lee YY,Erdogan A,Rao SS.How to perform and assess colonic manometry and barostat study in chronic constipation.J Neurogastroenterol Motil 2014;20:547-552[PMID:25230902 DOI:10.5056/jnm14056]
31 Parthasarathy G,Ravi K,Camilleri M,Andrews C,Szarka LA,Low PA,Zinsmeister AR,Bharucha AE.Effect of neostigmine on gastroduodenal motility in patients with suspected gastrointestinal motility disorders.Neurogastroenterol Motil 2015;27:1736-1746[PMID:26387781 DOI:10.1111/nmo.12669]
32 Bharucha AE,Low PA,Camilleri M,Burton D,Gehrking TL,Zinsmeister AR.Pilot study of pyridostigmine in constipated patients with autonomic neuropathy.Clin Auton Res 2008;18:194-202[PMID:18622640 DOI:10.1007/s10286-008-0476-x]
33 Wedlake L,A'Hern R,Russell D,Thomas K,Walters JR,Andreyev HJ.Systematic review:the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome.Aliment Pharmacol Ther 2009;30:707-717[PMID:19570102 DOI:10.1111/j.1365-2036.2009.04081.x]
34 Johnston IM,Nolan JD,Pattni SS,Appleby RN,Zhang JH,Kennie SL,Madhan GK,Jameie-Oskooei S,Pathmasrirengam S,Lin J,Hong A,Dixon PH,Williamson C,Walters JR.Characterizing Factors Associated With Differences in FGF19 Blood Levels and Synthesis in Patients With Primary Bile Acid Diarrhea.Am J Gastroenterol 2016;111:423-432[PMID:26856750 DOI:10.1038/ajg.2015.424]
35 Wong BS,Camilleri M,Carlson PJ,Guicciardi ME,Burton D,McKinzie S,Rao AS,Zinsmeister AR,Gores GJ.A Klothoβvariant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea.Gastroenterology 2011;140:1934-1942[PMID:21396369 DOI:10.1053/j.gastro.2011.02.063]
36 Camilleri M.Bile Acid diarrhea:prevalence,pathogenesis,and therapy.Gut Liver 2015;9:332-339[PMID:25918262 DOI:10.5009/gnl14397]
37 Peleman C,Camilleri M,Busciglio I,Burton D,Donato L,Zinsmeister AR.Colonic Transit and Bile Acid Synthesis or Excretion in Patients With Irritable Bowel Syndrome-Diarrhea Without Bile Acid Malabsorption.Clin Gastroenterol Hepatol 2017;15:720-727.e1[PMID:27856362 DOI:10.1016/j.cgh.2016.11.012]
38 Sauter GH,Münzing W,von Ritter C,Paumgartner G.Bile acid malabsorption as a cause of chronic diarrhea:diagnostic value of 7alpha-hydroxy-4-cholesten-3-one in serum.Dig Dis Sci 1999;44:14-19[PMID:9952217]
39 Lomer MC,Parkes GC,Sanderson JD.Review article:lactose intolerance in clinical practice--myths and realities.Aliment Pharmacol Ther 2008;27:93-103[PMID:17956597 DOI:10.1111/j.1365-2036.2007.03557.x]
40 Deng Y,Misselwitz B,Dai N,Fox M.Lactose Intolerance in Adults:Biological Mechanism and Dietary Management.Nutrients 2015;7:8020-8035[PMID:26393648 DOI:10.3390/nu7095380]
41 Tolliver BA,Herrera JL,DiPalma JA.Evaluation of patients who meet clinical criteria for irritable bowel syndrome.Am J Gastroenterol 1994;89:176-178[PMID:8304298]
42 Suarez FL,Savaiano DA,Levitt MD.A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance.N Engl J Med 1995;333:1-4[PMID:7776987 DOI:10.1056/NEJM199507063330101]
43 Wilder-Smith CH,Olesen SS,Materna A,Drewes AM.Fermentable Sugar Ingestion,Gas Production,and Gastrointestinal and Central Nervous System Symptoms in Patients With Functional Disorders.Gastroenterology 2018;155:1034-1044.e6[PMID:30009815 DOI:10.1053/j.gastro.2018.07.013]
44 Townley RR,Khaw KT,Shwachman H.Quantitative assay of disaccharidase activities of small intestinal mucosal biopsy specimens in infancy and childhood.Pediatrics 1965;36:911-921[PMID:5846834]
45 Saulnier DM,Ringel Y,Heyman MB,Foster JA,Bercik P,Shulman RJ,Versalovic J,Verdu EF,Dinan TG,Hecht G,Guarner F.The intestinal microbiome,probiotics and prebiotics in neurogastroenterology.Gut Microbes 2013;4:17-27[PMID:23202796 DOI:10.4161/gmic.22973]
46 Quigley EMM.Prebiotics and Probiotics in Digestive Health.Clin Gastroenterol Hepatol 2019;17:333-344[PMID:30267869 DOI:10.1016/j.cgh.2018.09.028]
47 Schnabel L,Buscail C,Sabate JM,Bouchoucha M,Kesse-Guyot E,Allès B,Touvier M,Monteiro CA,Hercberg S,Benamouzig R,Julia C.Association Between Ultra-Processed Food Consumption and Functional Gastrointestinal Disorders:Results From the French NutriNet-SantéCohort.Am JGastroenterol 2018;113:1217-1228[PMID:29904158 DOI:10.1038/s41395-018-0137-1]
48 Mayer EA,Savidge T,Shulman RJ.Brain-gut microbiome interactions and functional bowel disorders.Gastroenterology 2014;146:1500-1512[PMID:24583088 DOI:10.1053/j.gastro.2014.02.037]
49 Levy RL,Olden KW,Naliboff BD,Bradley LA,Francisconi C,Drossman DA,Creed F.Psychosocial aspects of the functional gastrointestinal disorders.Gastroenterology 2006;130:1447-1458[PMID:16678558 DOI:10.1053/j.gastro.2005.11.057]
50 De Palma G,Lynch MD,Lu J,Dang VT,Deng Y,Jury J,Umeh G,Miranda PM,Pigrau Pastor M,Sidani S,Pinto-Sanchez MI,Philip V,McLean PG,Hagelsieb MG,Surette MG,Bergonzelli GE,Verdu EF,Britz-McKibbin P,Neufeld JD,Collins SM,Bercik P.Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice.Sci Transl Med 2017;9[PMID:28251905 DOI:10.1126/scitranslmed.aaf6397]
51 Palsson OS,Whitehead WE.Psychological treatments in functional gastrointestinal disorders:a primer for the gastroenterologist.Clin Gastroenterol Hepatol 2013;11:208-16;quiz e22-3[PMID:23103907 DOI:10.1016/j.cgh.2012.10.031]
52 Bednarska O,Walter SA,Casado-Bedmar M,Str?m M,Salvo-Romero E,Vicario M,Mayer EA,Keita?V.Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome.Gastroenterology 2017;153:948-960.e3[PMID:28711627 DOI:10.1053/j.gastro.2017.06.051]
53 Camilleri M,Lasch K,Zhou W.Irritable bowel syndrome:methods,mechanisms,and pathophysiology.The confluence of increased permeability,inflammation,and pain in irritable bowel syndrome.Am JPhysiol Gastrointest Liver Physiol 2012;303:G775-G785[PMID:22837345 DOI:10.1152/ajpgi.00155.2012]
54 Turcotte JF,Kao D,Mah SJ,Claggett B,Saltzman JR,Fedorak RN,Liu JJ.Breaks in the wall:increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy(with videos).Gastrointest Endosc 2013;77:624-630[PMID:23357497 DOI:10.1016/j.gie.2012.11.006]
55 Fritscher-Ravens A,Schuppan D,Ellrichmann M,Schoch S,R?cken C,Brasch J,Bethge J,B?ttner M,Klose J,Milla PJ.Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome.Gastroenterology 2014;147:1012-20.e4[PMID:25083606 DOI:10.1053/j.gastro.2014.07.046]
56 Witt ST,Bednarska O,Keita?V,Icenhour A,Jones MP,Elsenbruch S,S?derholm JD,Engstr?m M,Mayer EA,Walter S.Interactions between gut permeability and brain structure and function in health and irritable bowel syndrome.Neuroimage Clin 2018[PMID:30472166 DOI:10.1016/j.nicl.2018.11.012]
57 Ma ZF,Yusof N,Hamid N,Lawenko RM,Mohammad WMZW,Liong MT,Sugahara H,Odamaki T,Xiao J,Lee YY.Bifidobacterium infantis M-63 improves mental health in victims with irritable bowel syndrome developed after a major flood disaster.Benef Microbes 2018;1-10[PMID:30525951 DOI:10.3920/BM2018.0008]
58 Vaughn BP,Rank KM,Khoruts A.Fecal Microbiota Transplantation:Current Status in Treatment of GIand Liver Disease.Clin Gastroenterol Hepatol 2019;17:353-361[PMID:30055267 DOI:10.1016/j.cgh.2018.07.026]
59 Drossman DA,Tack J,Ford AC,Szigethy E,T?rnblom H,Van Oudenhove L.Neuromodulators for Functional Gastrointestinal Disorders(Disorders of Gut-Brain Interaction):A Rome Foundation Working Team Report.Gastroenterology 2018;154:1140-1171.e1[PMID:29274869 DOI:10.1053/j.gastro.2017.11.279]
60 D'Souza DL,Levasseur LM,Nezamis J,Robbins DK,Simms L,Koch KM.Effect of alosetron on the pharmacokinetics of alprazolam.J Clin Pharmacol 2001;41:452-454[PMID:11304902]
61 Camilleri M.The role of pharmacogenetics in nonmalignant gastrointestinal diseases.Nat Rev Gastroenterol Hepatol 2012;9:173-184[PMID:22310916 DOI:10.1038/nrgastro.2012.2]
62 Li Y,Nie Y,Xie J,Tang W,Liang P,Sha W,Yang H,Zhou Y.The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients.Dig Dis Sci 2007;52:2942-2949[PMID:17394071 DOI:10.1007/s10620-006-9679-y]
63 Camilleri M,Carlson P,Acosta A,Busciglio I,Nair AA,Gibbons SJ,Farrugia G,Klee EW.RNAsequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea:a pilot case-control study.Am J Physiol Gastrointest Liver Physiol 2014;306:G1089-G1098[PMID:24763552 DOI:10.1152/ajpgi.00068.2014]
64 Camilleri M,Carlson P,Valentin N,Acosta A,O'Neill J,Eckert D,Dyer R,Na J,Klee EW,Murray JA.Pilot study of small bowel mucosal gene expression in patients with irritable bowel syndrome with diarrhea.Am J Physiol Gastrointest Liver Physiol 2016;311:G365-G376[PMID:27445342 DOI:10.1152/ajpgi.00037.2016]
65 Gikas A,Triantafillidis JK.The role of primary care physicians in early diagnosis and treatment of chronic gastrointestinal diseases.Int J Gen Med 2014;7:159-173[PMID:24648750 DOI:10.2147/IJGM.S58888]
66 Tack J,Pokrotnieks J,Urbonas G,Banciu C,Yakusevich V,Bunganic I,T?rnblom H,Kleban Y,Eavis P,Tsuchikawa M,Miyagawa T.Long-term safety and efficacy of acotiamide in functional dyspepsia(postprandial distress syndrome)-results from the European phase 3 open-label safety trial.Neurogastroenterol Motil 2018;30:e13284[PMID:29315999 DOI:10.1111/nmo.13284]
67 Camilleri M,Acosta A,Busciglio I,Boldingh A,Dyer RB,Zinsmeister AR,Lueke A,Gray A,Donato LJ.Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome.Aliment Pharmacol Ther 2015;41:438-448[PMID:25594801 DOI:10.1111/apt.13065]
68 Wilcox C,Turner J,Green J.Systematic review:the management of chronic diarrhoea due to bile acid malabsorption.Aliment Pharmacol Ther 2014;39:923-939[PMID:24602022 DOI:10.1111/apt.12684]
69 Camilleri M,Kerstens R,Rykx A,Vandeplassche L.A placebo-controlled trial of prucalopride for severe chronic constipation.N Engl J Med 2008;358:2344-2354[PMID:18509121 DOI:10.1056/NEJ-Moa0800670]
70 Ford AC,Brandt LJ,Young C,Chey WD,Foxx-Orenstein AE,Moayyedi P.Efficacy of 5-HT3antagonists and 5-HT4 agonists in irritable bowel syndrome:systematic review and meta-analysis.Am JGastroenterol 2009;104:1831-1843;quiz 1844[PMID:19471254 DOI:10.1038/ajg.2009.223]